|
Market Closed -
Nasdaq
16:00:00 2026-09-17 EDT
|
5-day change | 1st Jan Change | ||
| 5.280 USD | -2.40% |
|
-13.01% | +162.69% |
| 09-11 | HEALTH ROUNDS-Experimental eye drops ease night vision problems for drivers | RE |
| 09-10 | Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OPUS GENETICS, INC. | Other Pharmaceuticals | -2.40% | -13.01% | +162.69% | +269.23% | +1.73% | 450M |  | | |
- Stock Market
- Stocks
- IRD Stock
- Charts Opus Genetics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
